πŸ‡ΊπŸ‡Έ FDA
Patent

US 7173039

Protein kinase inhibitors

granted A61PA61P17/06A61P19/02

Quick answer

US patent 7173039 (Protein kinase inhibitors) held by Theravance, Inc. expires Mon Feb 01 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance, Inc.
Grant date
Tue Feb 06 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 01 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61P, A61P17/06, A61P19/02, A61P3/10